Randomized phase II study of two different schedules of gemcitabine and oral S-1 in <font color="red">chemo_2</font> <font color="red">-_2</font> <font color="red">naïve_2</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">advanced_2</font> <font color="red">non_2</font> <font color="red">-_2</font> <font color="red">small_2</font> <font color="red">cell_2</font> <font color="red">lung_2</font> <font color="red">cancer_2</font> <font color="red">._2</font> 
<br>
<br> INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in <font color="red">chemo_2</font> <font color="red">-_2</font> <font color="red">naïve_2</font> <font color="red">non_2</font> <font color="red">-_2</font> <font color="red">small_2</font> <font color="red">cell_2</font> <font color="red">lung_2</font> <font color="red">cancer_2</font> <font color="red">patients_2</font> <font color="red">._2</font> 
<br> METHODS <font color="red">Patients_2</font> <font color="red">with_2</font> <font color="red">chemo_2</font> <font color="red">-_2</font> <font color="red">naïve_2</font> <font color="red">stage_2</font> <font color="red">IIIB_2</font> <font color="red">/_2</font> <font color="red">IV_2</font> <font color="red">non_2</font> <font color="red">-_2</font> <font color="red">small_2</font> <font color="red">cell_2</font> <font color="red">lung_2</font> <font color="red">cancer_2</font> were randomized into two treatment arms . Patients were given oral S-1 ( 60 mg / m / d , twice a day ) from days 1 to 14 with gemcitabine ( 1000 mg / m / d ) on days 1 and 8 ( arm A ) or on days 8 and 15 ( arm B ) . This cycle was repeated every 21 days . 
<br> RESULTS <font color="red">A_1</font> <font color="red">total_1</font> <font color="red">of_1</font> <font color="red">80_2</font> <font color="red">patients_2</font> <font color="red">were_2</font> <font color="red">entered_2</font> <font color="red">in_2</font> <font color="red">this_2</font> <font color="red">trial_2</font> <font color="red">._2</font> The primary end point of this study was response rate . The response rates of arm A and arm B were 22.0 and 28.9% , respectively ( p = 0.606 ) . Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm B. Median time to progression in arm A was 4.1 months and 5.5 months in arm B. Median survival time in arm A and arm B was 15.5 months and 18.8 months , respectively . The toxicity profile was relatively mild and did not differ very much between two arms . 
<br> CONCLUSION The combination of gemcitabine and S-1 was determined to be feasible and effective for <font color="red">advanced_1</font> <font color="red">non_1</font> <font color="red">-_1</font> <font color="red">small_1</font> <font color="red">cell_1</font> <font color="red">lung_1</font> <font color="red">cancer_1</font> <font color="red">._1</font> We selected arm B for further studies because of its higher response rate and survival data .